SCHEMBL20138262

SCHEMBL20138262

Cc1cnnc(C)c1CN1C(=O)COc2c(C)cc(-c3ccc4c(c3)C(=O)NCC4)nc21

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.37
PARP1 P09874 4/20 0.35
PARP10 Q53GL7 4/20 0.35
CD274 Q9NZQ7 1/20 0.32
MAPKAPK2 P49137 1/20 0.32
GABRG2 P18507 2/20 0.32
GABRB3 P28472 2/20 0.32
GABRA5 P31644 2/20 0.32
PRF1 P14222 1/20 0.31
SLC5A2 P31639 2/20 0.31
SLC5A1 P13866 1/20 0.31
F7 P08709 1/20 0.31
F3 P13726 1/20 0.31
CDK4 P11802 1/20 0.30
CCNA2 P20248 1/20 0.30
CDK2 P24941 1/20 0.30
CDK6 Q00534 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20137915 0.85 MAPK1 (0.41) MAPK1PARP1PARP10CD274MAPKAPK2
SCHEMBL20138220 0.83 CDK4 (0.39) MAPK1PARP1PARP10CD274MAPKAPK2
SCHEMBL20138000 0.78 MAPK1 (0.38) MAPK1PARP1PARP10CD274MAPKAPK2
SCHEMBL20138109 0.77 MAPK1 (0.43) MAPK1PARP1PARP10CD274MAPKAPK2
SCHEMBL20138304 0.76 SLC5A2 (0.33) SLC5A2SLC5A1
SCHEMBL20137967 0.73 MAPK1 (0.43) MAPK1PARP1PARP10CD274MAPKAPK2
SCHEMBL20138141 0.72 CD274 (0.37) MAPK1PARP1PARP10CD274MAPKAPK2
SCHEMBL20138307 0.70 MAPK1 (0.42) MAPK1PARP1PARP10CD274MAPKAPK2
SCHEMBL18305060 0.69 CDK4 (0.41) MAPK1PARP1PARP10CD274MAPKAPK2
SCHEMBL20138147 0.69 MAPK1 (0.44) MAPK1PARP1PARP10CD274MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10287299-B2 Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity UCB BIOPHARMA SPRL (BE) 2019-05-14 US disclosed
US-20180134728-A1 Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity UCB S.A. (BE) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134728-A1 Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity TNF, NFKBIA, TNFRSF1A MAPK1 1235/4885PARP1 1553/4885PARP10 1687/4885
US-10287299-B2 Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity TNF, TNFRSF1A, NFKBIA MAPK1 1268/4885PARP1 2142/4885PARP10 3857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.